Surgery Websites
Transplant Surgery »  Meet the Team »  Pediatric Nephrology »  Anthony A. Portale, M.D.
Anthony A. Portale, M.D.

Anthony A. Portale, M.D.

  • Professor in Residence
  • Division of Pediatric Nephrology
  • Department of  Pediatrics
  • Director, Pediatric Dialysis Program
Open Popup

Education

State University of New York at Buffalo 1974, M.D.

Fellowships

  • UCSF Medical Center, Pediatric Nephrology

Board Certifications

  • American Board of Pediatrics - General Pediatrics
  • American Board of Pediatrics - Pediatric Nephrology Subspecialty

Clinical Expertise

  • Acute Kidney Failure
  • Chronic Kidney Disease
  • End-Stage Renal Disease
  • Living Donor Kidney Transplantation
  • Pediatric bone and Mineral Disorders
  • Pediatric Kidney Transplantation
  • Pediatric Transplant Nephrology

Research Interests

  • Bone diseases in children
  • Genetic and acquired disorders of calcium
  • Pphosphorus and vitamin D metabolism

Website Links

Biography

Dr. Anthony A. Portale, a pediatric kidney specialist, is director of the Pediatric Dialysis Program. He is an expert in genetic kidney and renal tubular diseases, disorder of bone and mineral metabolism, and acute kidney failure.

A graduate of St. Joseph's University in Philadelphia, he earned a medical degree at State University of New York at Buffalo and completed a pediatric nephrology fellowship at UCSF Medical Center. His research, funded by the National Institutes of Health, he has produced more than 80 publications in the medical and scientific literature focused on genetic and acquired disorders of calcium, phosphorus and vitamin D metabolism and bone diseases in children.

Research & Funding

Data provided by UCSF Profiles, powered by CTSI
  • Bio-Organic Biomedical Mass Spectrometry Resource
    Sponsor:
    Sponsor ID:
    Funding Period:
    Mar 1982
    -
    May 2015
    Co-Investigator
  • Disordered Mineral Metabolism in the CKiD Children: Role of FGF-23
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jul 2010
    -
    Jun 2014
    Principal Investigator
  • General Clinical Research Center
    Sponsor:
    Sponsor ID:
    Funding Period:
    Dec 1974
    -
    Mar 2009
    Co-Investigator
  • PEDIATRIC CLINICAL RESEARCH CENTER
    Sponsor:
    Sponsor ID:
    Funding Period:
    Dec 1981
    -
    Mar 2007
    Co-Investigator
  • MOLECULAR REGULATION OF 1,25(OH)2D PRODUCTION
    Sponsor:
    Sponsor ID:
    Funding Period:
    Aug 1998
    -
    Jul 2005
    Principal Investigator

Clinical Trials

Data provided by UCSF Profiles, powered by CTSI

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 98
Data provided by UCSF Profiles, powered by CTSI
  1. Imel EA, Glorieux FH, Whyte MP, Portale AA, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Chen A, Roberts MS, Ward LM. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level. J Clin Endocrinol Metab. 2023 10 18; 108(11):2990-2998. View in PubMed
  2. Weber TJ, Imel EA, Carpenter TO, Peacock M, Portale AA, Hetzer J, Merritt JL, Insogna K. Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia. J Clin Endocrinol Metab. 2022 12 17; 108(1):155-165. View in PubMed
  3. Brandi ML, Jan de Beur S, Briot K, Carpenter T, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Imel EA, Ing SW, Insogna K, Ito N, Javaid K, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Portale A, Ralston SH, Tanaka H, Weber TJ, Yoo HW, Sun W, Williams A, Nixon A, Takeuchi Y. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcif Tissue Int. 2022 10; 111(4):409-418. View in PubMed
  4. Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, Högler W, Simmons JH, Gottesman GS, Padidela R, Namba N, Cheong HI, Nilsson O, Mao M, Chen A, Skrinar A, Roberts MS, Imel EA. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. J Clin Endocrinol Metab. 2022 07 14; 107(8):e3241-e3253. View in PubMed
  5. Hanudel MR, Laster ML, Portale AA, Dokras A, Quigley RP, Guzman GAL, Zaritsky JJ, Hayde NA, Kaskel FJ, Mitsnefes MM, Ramirez JA, Imani PD, Srivaths PR, Kogon AJ, Denburg MR, Blydt-Hansen TD, Reyes LZ, Greenbaum LA, Weidemann DK, Warady BA, Elashoff DA, Mendley SR, Isakova T, Salusky IB. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial. Pediatr Nephrol. 2022 11; 37(11):2547-2557. View in PubMed
  6. View All Publications

 

 
Site Directory
    X